NASDAQ:OBIO Orchestra BioMed Q1 2025 Earnings Report $4.01 -0.01 (-0.25%) Closing price 05/5/2026 04:00 PM EasternExtended Trading$4.01 0.00 (0.00%) As of 05/5/2026 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. ProfileEarnings HistoryForecast Orchestra BioMed EPS ResultsActual EPS-$0.49Consensus EPS -$0.46Beat/MissMissed by -$0.03One Year Ago EPSN/AOrchestra BioMed Revenue ResultsActual Revenue$0.87 millionExpected Revenue$0.39 millionBeat/MissBeat by +$480.00 thousandYoY Revenue GrowthN/AOrchestra BioMed Announcement DetailsQuarterQ1 2025Date5/12/2025TimeAfter Market ClosesConference Call DateSunday, May 11, 2025Conference Call Time6:00PM ETUpcoming EarningsOrchestra BioMed's Q1 2026 earnings is estimated for Monday, May 11, 2026, based on past reporting schedules, with a conference call scheduled at 4:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.Q1 2026 Earnings ReportConference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) Orchestra BioMed Earnings HeadlinesFDA Grants Orchestra BioMed Additional Breakthrough Device Designation for AVIM TherapyApril 30, 2026 | globenewswire.comOrchestra BioMed Reports Positive Results from MODERATO II Trial for Atrioventricular Interval Modulation Therapy in Hypertension ManagementApril 23, 2026 | quiverquant.comQI’m sounding the alarmMeta is cutting 10% of its workforce. Microsoft offered voluntary retirement to 7% of U.S. employees. Oracle, Amazon, Snap, and Block have done the same. Most assume this is about AI - but investor Porter Stansberry says the real driver runs far deeper. Goldman Sachs estimates 12,400 Americans are being financially harmed every day by this shift, while others grow wealthier. Stansberry - who predicted the internet economy's rise and recommended Amazon, Qualcomm, and Texas Instruments before they were household names - is now releasing a new investigation he calls The Final Displacement. | Porter & Company (Ad)Orchestra BioMed to Present AVIM Therapy Clinical and Mechanistic Data at HRS 2026April 23, 2026 | globenewswire.comOrchestra BioMed Holdings (OBIO) price target decreased by 11.17% to 11.39April 9, 2026 | msn.comOrchestra BioMed reports 2025 results, advances pivotal clinical trialsMarch 17, 2026 | msn.comSee More Orchestra BioMed Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Orchestra BioMed? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Orchestra BioMed and other key companies, straight to your email. Email Address About Orchestra BioMedOrchestra BioMed (NASDAQ:OBIO), Inc. (NASDAQ: OBIO) is a clinical‐stage biopharmaceutical company dedicated to developing targeted therapies for inflammatory, fibrotic and oncologic diseases. The company’s research focuses on novel small-molecule programs designed to address high‐unmet-need conditions by leveraging proprietary prodrug and targeted inhibitor platforms. Orchestra BioMed’s pipeline includes lead candidates such as OBI-3424, a prodrug activated by AKR1C3 for the treatment of select solid tumors, and next-generation modulators aimed at suppressing pathological inflammation and fibrosis. Orchestra BioMed conducts early‐ and mid-stage clinical studies in North America, working closely with key opinion leaders and academic centers to advance its programs. The company’s development strategy emphasizes streamlined trial design and biomarker-driven patient selection, with the goal of demonstrating safety and efficacy in well-defined patient populations. In parallel, Orchestra evaluates combination approaches and seeks strategic collaborations to broaden the therapeutic reach of its candidates across multiple disease indications. Headquartered in the United States, Orchestra BioMed is led by a management team with extensive experience in drug discovery, clinical development and regulatory affairs. The company operates under a governance framework committed to scientific rigor and transparent communication with investors and collaborators. Orchestra BioMed continues to build its capabilities through targeted investments in research infrastructure and external partnerships, positioning itself to address significant challenges in fibrotic, inflammatory and oncologic disease management.View Orchestra BioMed ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Palantir Drops After a Blowout Q1—What Investors Should KnowShopify’s Valuation Crisis Creates Opportunity in 2026onsemi Stock Dips After Earnings: Why the Dip Is BuyableTSLA: 3 Reasons the Stock Could Hit $400 in MayNebius Breaks Out to All-Time Highs—Here's What's Driving It.3 Reasons Analysts Love DexComMonolithic Power Systems: AI Stock Beat, Raised and Upgraded Post-Earnings Upcoming Earnings AppLovin (5/6/2026)ARM (5/6/2026)DoorDash (5/6/2026)Fortinet (5/6/2026)Marriott International (5/6/2026)Warner Bros. Discovery (5/6/2026)Apollo Global Management (5/6/2026)Cencora (5/6/2026)Cenovus Energy (5/6/2026)CVS Health (5/6/2026) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
